D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs ##### Up next ![One Heung Kong "Eye of the Future" Unveiled, Crafting a New Global Landmark for Cultural Dialogue](https://i0.wp.com/mma.prnasia.com/media2/2842269/image_841870_30220960.jpg?resize=200%2C110&ssl=1 "One Heung Kong "Eye of the Future" Unveiled, Crafting a New Global Landmark for Cultural Dialogue") [](https://thailandbusinessnews.net/press-release/one-heung-kong-eye-of-the-future-unveiled-crafting-a-new-global-landmark-for-cultural-dialogue/) ###### [One Heung Kong "Eye of the Future" Unveiled, Crafting a New Global Landmark for Cultural Dialogue](https://thailandbusinessnews.net/press-release/one-heung-kong-eye-of-the-future-unveiled-crafting-a-new-global-landmark-for-cultural-dialogue/) Published on 10 December 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2758996/D3_BIO_DeShengJi_Logo.jpg?p=medium600 "logo") SHANGHAI, Dec. 10, 2025 /PRNewswire/ — D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio’s innovative pipeline and its global development strategy. Proceeds from this financing will primarily support the planned global Phase III pivotal program for the company’s lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination therapies for KRAS G12C-mutant cancers across key countries and regions, including the United States, China, and the European Union, to facilitate global regulatory submissions. Furthermore, the funding will facilitate ongoing development of D3 Bio’s comprehensive pipeline of targeted and immuno-oncology programs, which are centred on innovative mechanisms with first-in-class or best-in-class potential. Dr. George Chen, Founder, Chairman, and CEO of D3 Bio, stated, "The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations, and global development capabilities. This funding enables us to advance our lead program into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally." Dr. Antoine Yver, Member of the Board of Directors and Scientific Committee of D3 Bio, stated, "This financing demonstrates that the swift and effective pursuit of the best- or first-in-class science is meaningful to society, and validates D3 Bio’s leading innovation, scientific vision and development strategy. It also highlights the unique potential of elisrasib for individuals affected by KRAS G12C-mutant cancers." About D3 BioD3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company’s discovery and development platforms leverage proprietary clinical insight and biomarker strategies to create novel and clinically meaningful therapies for patients in need. D3 Bio’s oncology programs target driver mutations or critical immune pathways and are designed to have first-in-class or best-in-class potential. D3 Bio owns global rights for all of its programs. For more information, please visit [www.d3bio.com](https://www.d3bio.com/). [Source link ](https://www.prnasia.com/story/archive/4842429_AE42429_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/htx-dao-celebrates-first-anniversary-with-explosive-growth-and-bold-plans-for-2025/) ![HTX DAO Celebrates First Anniversary with Explosive Growth and Bold Plans for 2025](https://i0.wp.com/thailandbusinessnews.net/wp-content/uploads/2025/02/1739375623_image_ID__Logo.jpg?resize=260%2C140&ssl=1 "HTX DAO Celebrates First Anniversary with Explosive Growth and Bold Plans for 2025") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## HTX DAO Celebrates First Anniversary with Explosive Growth and Bold Plans for 2025 SINGAPORE, Feb. 12, 2025 /PRNewswire/ — HTX DAO, a leading decentralized autonomous… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 12, 2025 [](https://thailandbusinessnews.net/press-release/tcl-technology-pioneers-a-low-carbon-future-through-advanced-water-management-and-clean-technology-innovation/) ![TCL Technology Pioneers a Low-Carbon Future Through Advanced Water Management and Clean Technology Innovation](https://i0.wp.com/mma.prnasia.com/media2/2849659/TCL_Zhonghuan_s_Organizational_Structure_Water_Management.jpg?resize=260%2C140&ssl=1 "TCL Technology Pioneers a Low-Carbon Future Through Advanced Water Management and Clean Technology Innovation") - [Press Release](https://thailandbusinessnews.net/category/press-release/) - [Tech](https://thailandbusinessnews.net/category/tech/) ## TCL Technology Pioneers a Low-Carbon Future Through Advanced Water Management and Clean Technology Innovation SHENZHEN, China, Dec. 19, 2025 /PRNewswire/ — Following the release of its… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - December 19, 2025 [](https://thailandbusinessnews.net/press-release/cheche-group-partners-with-faw-bestune-to-launch-industry-first-fully-digital-one-stop-vehicle-delivery-service/) ## Cheche Group Partners with FAW Bestune to Launch Industry-First Fully Digital One-Stop Vehicle Delivery Service BEIJING, Dec. 4, 2025 /PRNewswire/ — Cheche Group Inc. (NASDAQ: CCG) ("Cheche"… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - December 4, 2025 ##### Most Read - [![DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dbs-hong-kong-partners-with-visa-preface-to-empower-customers-with-ai-readiness-skills-for-the-future-of-intelligent-payments/ "DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments") [DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments](https://thailandbusinessnews.net/press-release/dbs-hong-kong-partners-with-visa-preface-to-empower-customers-with-ai-readiness-skills-for-the-future-of-intelligent-payments/ "DBS Hong Kong Partners with Visa, Preface to empower Customers with AI Readiness skills, for the Future of Intelligent Payments") - [![Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/piramal-pharma-limited-completes-acquisition-of-controlling-stake-in-yapan-bio-private-limited/ "Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited") [Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited](https://thailandbusinessnews.net/press-release/piramal-pharma-limited-completes-acquisition-of-controlling-stake-in-yapan-bio-private-limited/ "Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited") - [![ZTO Reports Second Quarter 2026 Unaudited Financial Results](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/zto-reports-second-quarter-2026-unaudited-financial-results/ "ZTO Reports Second Quarter 2026 Unaudited Financial Results") [ZTO Reports Second Quarter 2026 Unaudited Financial Results](https://thailandbusinessnews.net/press-release/zto-reports-second-quarter-2026-unaudited-financial-results/ "ZTO Reports Second Quarter 2026 Unaudited Financial Results") - [![GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gsks-blenrep-belantamab-mafodotin-combinations-approved-in-singapore-for-treatment-of-relapsed-refractory-multiple-myeloma/ "GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma") [GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma](https://thailandbusinessnews.net/press-release/gsks-blenrep-belantamab-mafodotin-combinations-approved-in-singapore-for-treatment-of-relapsed-refractory-multiple-myeloma/ "GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma") - [![Everest Medicines Announces Interim Results for First Half of 2026](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/everest-medicines-announces-interim-results-for-first-half-of-2026/ "Everest Medicines Announces Interim Results for First Half of 2026") [Everest Medicines Announces Interim Results for First Half of 2026](https://thailandbusinessnews.net/press-release/everest-medicines-announces-interim-results-for-first-half-of-2026/ "Everest Medicines Announces Interim Results for First Half of 2026") - [![Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/taiwantrade-com-brings-taiwans-ict-excellence-to-computex-2025/ "Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025") [Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025](https://thailandbusinessnews.net/press-release/taiwantrade-com-brings-taiwans-ict-excellence-to-computex-2025/ "Taiwantrade.com Brings Taiwan's ICT Excellence to COMPUTEX 2025") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/ping-an-reports-1h-2026-results/) ## Ping An Reports 1H 2026 Results Operating Profit[1] Grows 8.3% YoY; Net Profit[2] Surges 36.1% YoY; Interim Dividend… [](https://thailandbusinessnews.net/press-release/advasa-holdings-inc-announces-revised-expected-trading-commencement-date-for-common-stock-on-the-nasdaq-global-market/) ## Advasa Holdings, Inc. Announces Revised Expected Trading Commencement Date for Common Stock on the Nasdaq Global Market Common Stock Now Expected to Begin Trading on August 25, 2026 Under… [](https://thailandbusinessnews.net/press-release/china-infrastructure-logistics-group-strategically-partners-with-wuhan-new-materials-to-enter-the-blue-ocean-of-port-protection-new-materials/) ## China Infrastructure & Logistics Group Strategically Partners with Wuhan New Materials to Enter the Blue Ocean of Port Protection New Materials Providing "Port + New Materials" Integrated Supply Chain Solutions HONG KONG,… [](https://thailandbusinessnews.net/press-release/yunji-announces-first-half-2026-unaudited-financial-results/) ## Yunji Announces First Half 2026 Unaudited Financial Results HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ — Yunji Inc. ("Yunji" or…